【Company Recommendation】Emeishan Hongsen Biopharmaceutical Co., Ltd.

Company Introduction Emeishan Hongsen Biopharmaceutical Co., Ltd. is a national high-tech enterprise focusing on peptide fragments, protected amino acids, pharmaceutical intermediates, APIs, and CMO/CDMO fields. Business scope: an experienced project undertaking team escorts full life-cycle CMO/CDMO services; a GMP quality system that has been audited many times by domestic and foreign customers; the company has an independent technology R&D center, a provincial enterprise technology center, and Leshan Synthetic Biology Engineering Technology Research Center, providing one-stop services including process optimization, R&D, production, and sales. The company was established on February 18, 2011. It currently has more than 150 employees and more than 70 sets of various reactors ranging from 100L to 6300L, providing flexible and diversified cooperation models. Star Products 89030-95-5 Copper Peptide Copper peptide can effectively stimulate the biosynthesis of collagen in fibroblasts, thereby promoting rapid wound healing. It can also effectively block the neurotransmission of acetylcholine substances, thereby relaxing ...

• Source: drugdu
• 46
• June 26, 2026

China’s first ADC (Advanced Dioxide Doppler) to be submitted for market approval

On June 23, the CDE (Center for Drug Evaluation) website showed that Chia Tai Tianqing Pharmaceutical Group’s application for marketing authorization of vetectobactimab for injection was accepted. This monotherapy is indicated for patients with CLDN18.2-positive, locally advanced, or metastatic gastric/gastroesophageal junction adenocarcinoma who have received at least two lines of prior systemic therapy . Previously, this drug had been formally included in the CDE’s priority review and approval process . Screenshot source: CDE official website Vitacotobactam (development code: LM-302 ) is an antibody-drug conjugate (ADC) targeting Claudin18.2 (CLDN18.2) developed by Lixin Pharmaceuticals. It specifically binds to CLDN18.2-positive tumor cells, enters the cells via endocytosis, and releases small molecule toxins to achieve precise killing of tumor cells. In July 2025, China Biopharmaceutical announced that it would acquire 100% of Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. for a net consideration of approximately US$500 million , bringing the latter’s highly regarded bispecific antibody ...

• Source: drugdu
• 53
• June 25, 2026

Sanofi’s second autoimmune BTK inhibitor approved for marketing

On June 23, Sanofi announced that Tolebrutinib (trade name: Cenrifki) has been approved by the European Medicines Agency (EMA) for the treatment of relapse-free secondary progressive multiple sclerosis (SPMS). This drug is the first approved treatment for non-relapsing SPMS and Sanofi’s second approved autoimmune BTK inhibitor. Sanofi’s first autoimmune BTK inhibitor, Rilzabrutinib (trade name: Wayrilz ), was approved in the US and Europe in 2025.This approval was supported by the Phase III HERCULES study , which included 1131 patients with non-recurrent SPMS .Patients. Results showed that at a median follow-up of 133 weeks, the proportion of patients in the Tolebrutinib (60 mg, once daily) group who had confirmeddisability progression lasting at least 6 months was significantly lower than that inthe placebo group (22.6% vs 30.7%, HR=0.69, P=0.003).Multiple sclerosis (MS) is a chronic, immune-mediated neurodegenerative disease of the central nervous system that can lead to persistent and irreversible disability over time. ...

• Source: drugdu
• 51
• June 25, 2026

Qingfeng Pharmaceutical’s apalutamide tablets have been approved, adding another powerful tool to the field of anti-tumor therapy

According to the official website of the National Medical Products Administration (NMPA), the generic apalutamide tablets submitted by Kerui Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, were approved for production on May 19 and are considered to have passed the consistency evaluation. This is the third endocrine therapy chemical drug approved for Qingfeng Pharmaceutical, marking a new milestone in the company’s R&D and commercialization strategy in the field of prostate cancer treatment. 0 1 Apalutamide tablets: A new generation of androgen receptor inhibitors Blockbuster drugs for prostate cancer treatment Apalutamide is a new generation of oral, highly selective nonsteroidal androgen receptor (AR) inhibitors. It competitively blocks androgen binding by binding to the intracellular ligand-binding domain of AR with high affinity, inhibiting receptor conformational changes and nuclear translocation, and preventing AR translocation into the nucleus.¹ Simultaneously, it blocks the binding of AR to DNA response elements, inhibiting the transcription ...

• Source: drugdu
• 47
• June 25, 2026

PHARMCHINA——tHIS ASEAN

Organiser：Sinopharm Exhibition & APHM Time： July 28–30, 2026 Address：Kuala Lumpur Convention Centre, Kuala Lumpur City Centre, Kuala Lumpur, 50088, Malaysia Exhibition hall：Kuala Lumpur Convention Centre, Kuala Lumpur City Centre   Product range: Pharmaceuticals: Chemical drugs, Chinese patent medicines, ethnic medicines, OTC drugs, biological products Pharma R&D Supply Chain: R&D services, CRO, CMO, CDMO, MAH cooperation, registration consulting Chinese Herbal Medicines / Prepared Slices: Bulk herbal slices, traditional prepared slices, refined-packaging slices, small-packaging slices, direct-oral solid slices, wall-broken slices, food-medicine homology herbs & herbal teas, TCM formula granules, new-type prepared slices, raw Chinese herbs, TCM slice production equipment, TCM slice packaging, etc. TCM Wellness: Moxibustion & moxa products, TCM wellness clinics, foot bath & medicinal bath products, TCM beauty, Chinese medicinal oils/ointments, medicinal cuisine, health wine, etc. TCM Diagnostic & Treatment Equipment: TCM diagnostic equipment, TCM instruments, TCM pharmaceutical equipment, etc. Public Health & Protection: Masks, gloves, protective suits, goggles, disinfection products, ...

• Source: drugdu
• 54
• June 23, 2026

【EXPERT Q&A】What certifications are required for medical devices to enter the Saudi market?

Drugdu.com expert’s response:   The core of entering the Saudi market is mandatory registration and certification with the Saudi Food and Drug Authority (SFDA), along with a series of supporting requirements. The following breaks them down by priority. I. Core Certification That Must Be Completed: SFDA Medical Device Registration This is the only legal entry requirement for all medical devices. Unregistered products cannot clear customs or be sold. Registration Process: Submit registration application through the SFDA online system (MDMA / Saudi Drug Registration System) Submit complete technical documentation; SFDA conducts document review Medium-to-high risk products may be required to provide additional test reports or undergo on-site audits Upon approval, a registration certificate is issued (typically valid for 5 years, renewable upon expiry) II. Products Classified by Risk Level — Requirements Differ SFDA classifies medical devices into four classes. The higher the class, the stricter the review: Class I (Low Risk) — e.g., surgical blades, ...

• Source: drugdu
• 55
• June 22, 2026

Three Conversations We Heard Repeatedly at CPHI China 2026

Three days at CPHI China 2026 gave us the opportunity to meet pharmaceutical manufacturers, suppliers, buyers, and industry professionals from around the world. For Drugdu.com, exhibitions are not only about networking. They are also one of the best places to observe how the pharmaceutical industry is evolving and what companies are focusing on next. After hundreds of conversations across APIs, formulations, extracts, excipients, and pharmaceutical services, a few themes kept coming up. 1. Companies Are Looking for Their Next Growth Market One topic appeared repeatedly throughout the exhibition: Where should we focus next? Latin America. The Middle East. Southeast Asia. These regions were mentioned far more often than we expected. Many companies are no longer asking whether they should expand internationally. They are already active in global markets. The discussion has shifted toward market selection, resource allocation, and identifying the next region that offers sustainable growth. For many pharmaceutical companies, ...

• Source: drugdu
• 50
• June 20, 2026

【EXPERT Q&A】How to apply for a medical device business license?

Drugdu.com expert’s response:   Obtaining a Medical Device Distribution License — the key is to first clarify which class of devices you intend to distribute, as the process for Class II and Class III is completely different. Clarify: Are you applying for a “License” or “Filing”? Class I (Low Risk) — e.g., surgical scalpels, gauze, stethoscopes: Filing during business registration is sufficient. No license required. Class II (Medium Risk) — e.g., blood pressure monitors, thermometers, nebulizers: File with the municipal drug regulatory authority. This is not called a license. Class III (High Risk) — e.g., cardiac stents, CT scanners, ventilators, contact lenses: You must apply for a Medical Device Distribution License from the municipal drug regulatory authority. When people ask about a “license,” they usually mean Class III. The following covers Class III. Application Requirements (Five Mandatory Criteria — All Must Be Met) Personnel: The quality manager must hold a college degree or higher (or intermediate professional ...

• Source: drugdu
• 73
• June 19, 2026

BIO Asia Taiwan — the Asia Biotech Conference & Exhibition

Organiser：Taiwan Bio-Industry Development Association Time：July 15–19, 2026 Address：No. 1, Jingmao 2nd Road, Nangang District, Taipei Exhibition hall：Taipei Nangang Exhibition Center, Trade Center, Taipei   Product range: Pharmaceuticals: New drug development, vaccine preparations (gene therapy, cell therapy), generic drugs, active pharmaceutical ingredients (APIs), Chinese herbal medicine Medical Devices: Medical device R&D, medical electronics, medical imaging, medical instruments, composite medical materials Biotech Services & Testing: Genetic testing, reagents, biochips, cord blood, stem cells, medical services, clinical and pre-clinical trial services (CRO), contract manufacturing (CMO), logistics Equipment & Instruments: Instruments, pharmaceutical equipment (components), packaging, printing, turnkey plant equipment Beauty & Wellness: Medical aesthetic centers, beauty and skincare products, raw materials, packaging containers, beauty instruments, ODM/OEM design services Food & Health: Biotech raw materials, health foods, nutritional supplements, beverage industry, OEM/ODM Agriculture, Fisheries & Aquaculture: Aquaculture, floriculture, bio-fertilizers, bio-pesticides Biotech Funds & Venture Capital: Banking, securities advisory, venture capital, legal, accounting   About BIO ...

• Source: drugdu
• 64
• June 18, 2026

On June 16, foreign media suddenly reported several pieces of news about semaglutide. One was that Novo Nordisk’s oral weight-loss drug Wegovy would soon be launched in China; another was that Novo Nordisk made it clear: regulatory data protection for semaglutide in China will last until the second quarter of 2027, when generics will be able to enter the market. According to foreign media reports, both pieces of news came from Novo Nordisk’s Global President and CEO, Mike Doustdar. In the past few days, Novo Nordisk’s global management has happened to be visiting China. On June 15, Health News reported that Lei Haichao, Director of the National Health Commission, met with several Novo Nordisk executives, to discuss Novo Nordisk’s presence in China and its future strategy. The two major pieces of news above were very likely leaked during this public event, drawing strong market attention. The news about oral semaglutide ...

• Source: drugdu
• 79
• June 17, 2026